What is the Orange Book preface?
The “Orange Book” is the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. The preface is the introductory section that explains how the FDA organizes the listing, what the FDA means by “therapeutic equivalence,” and how readers should interpret the tables of approved products and coded drug information.
What does the FDA explain in the Orange Book preface?
Typically, the preface covers key reading instructions, including how to interpret:
- The drug product listings (approved drug entries and their identifiers)
- Therapeutic equivalence evaluations (how the FDA assigns equivalence ratings)
- Generic drug products vs. brand-name products in the database
- How codes are used to describe aspects of active ingredients, dosage forms, and other listing attributes
Why do people read the Orange Book preface?
People often read it to understand:
- How to correctly search for a drug and match the right active ingredient and dosage form
- What the FDA’s equivalence codes/ratings actually mean
- How to interpret the listing when doing patent/exclusivity research, regulatory planning, or compliance work
Does the Orange Book preface include legal or patent guidance?
The Orange Book is commonly used for patent and exclusivity research, but the preface is mainly about how to read the listing. For patent-related questions (listed patents, exclusivity timing, etc.), readers usually pair the preface with the Orange Book’s drug-specific entries and the FDA’s patent/exclusivity framework that the database supports.
Can you share the exact “Orange Book preface” text you mean?
The Orange Book content can differ by edition/year and by whether you’re looking at the eBook/PDF front matter or an online landing page. If you paste the preface text or tell me the edition/date (or share a link), I can summarize it precisely and explain the specific sections line by line.